NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis & Investment Frameworks
NewAmsterdam Pharma Company N.V. (NAMS) stock analysis on Invetso. Review NewAmsterdam Pharma Company N.V.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
NewAmsterdam Pharma Company N.V. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
NewAmsterdam Pharma Company N.V. Key Financial Metrics
- Market Cap: $2.26B
- Revenue: $22.50M
- ROE: -31.39%
- ROIC: -37.01%
- Dividend Yield: N/A
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.